Vaccinex (stock symbol: VCNX) Logo in transparent PNG and SVG formats

Vaccinex Logo large

Vaccinex Logo icon format

Vaccinex Logo large for dark backgrounds

Vaccinex Logo icon format for dark backgrounds

About Vaccinex

Vaccinex, Inc., a clinical-stage biotechnology company, focuses on treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed a proprietary drug discovery platform, ActivMAb that it is leveraging through strategic collaborations, by exploiting its unique capability to select antibodies against multi-pass membrane receptors. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.

  • Website domain: vaccinex.com
  • Employees: 39
  • Marketcap: $29.42 Million USD

Page last updated on:

August 20th, 2022

Categories: